Country for PR: United Kingdom
Contributor: PR Newswire Europe
Saturday, December 03 2022 - 00:53
Sirolimus Coated Balloon in BTK Treatment makes a bold presence at VEITH 2022 – Lights up NY Times Square, NASDAQ
TAMPA, Fla., Dec. 2, 2022 /PRNewswire-AsiaNet/ --

    VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus 
Coated Balloon in the treatment of Below-the-Knee (BTK) disease. Concept 
Medical Inc. [] hosted a lunch symposium titled 
'Sirolimus Coated Balloon in PAD Treatment: Choice of The Future' which 
explored the utility of Sirolimus Coated Balloon treatment in PAD. The session 
was chaired by Prof. Sahil Parikh, co-moderated by Prof. Edward Choke and Prof. 
Aloke Finn with interesting presentations by Prof. Ulf Teichgräber and Prof. 
Francesco Liistro.

    One of the highlights of the session was the follow up data of clinical 
outcomes of the XTOSI Trial.  XTOSI (Xtreme Touch Sirolimus coated PTA balloon) 
is a single arm trial for Sirolimus Coated Balloon (MagicTouch PTA) 
[] investigating the 
clinical use and safety of the device in the treatment of infrainguinal 
Peripheral Arterial Disease (PAD). This prospective, premarket, non-randomized, 
all comers single-arm study, led by PI Prof. Edward Choke enrolled 50 patients 
to study the Magic Touch PTA 
[] Sirolimus Coated 
Balloon (Concept Medical Inc.) [] at Sengkang 
General Hospital, Singapore. It is the world's first trial of Sirolimus Coated 
Balloon for BTK disease and has the longest follow up data. While the primary 
endpoints already suggested promising patency and safety at 6 months, the data 
presented at VEITH 2022 shed more light on the longer-term efficacy and the 
safety of the Sirolimus Coated Balloon.

    Prof. Edward Choke, further presented updates on the FUTURE SFA and FUTURE 
BTK RCTs, a family of randomised trials set to enrol 279 and 219 patients 
respectively, against standard uncoated balloon in 2:1 fashion and are ongoing 
in Singapore, Taiwan and Thailand. FUTURE BTK has already completed 25% of its 
enrolment target, credits to the principal investigators of all sites involved.

    Sirolimus Coated Balloon for PAD continues its march, knocking on the doors 
of the US and lighting up the iconic New York Times Square with a dazzling 
display of the study results of XTOSI and the recruitment status of the FUTURE 

    Watch the complete session to know more about exciting clinical data:

    Source: Concept Medical Inc.